Skip to main content
. Author manuscript; available in PMC: 2018 Jul 1.
Published in final edited form as: Pediatr Infect Dis J. 2017 Jul;36(7):645–653. doi: 10.1097/INF.0000000000001538

Figure 4.

Figure 4

Comparison of the simulated dalbavancin AUC0–120 estimates in pediatric subjects of age 3 months to 18 years using various age-dependent dosing regimens to the distribution of AUC0–120 estimates from the adult, phase 3 program (dalbavancin day 1 dose of 1000 mg). The solid line/shaded area represent median/90% confidence interval of AUC0–120 estimates from the adult, phase 3 program (dalbavancin day 1 dose of 1000 mg).